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Antibodies and reagents
All antibodies and reagents used in this study are described in the Appendix.
cell cultures
The DPSCs from rat and human were cultured as described in the Appendix. BMMSC culture was described previously (Yamaza et al., 2011). colony-forming units-Fibroblastic (cFu-F) Assay CFU-F assay was performed as described previously (Yamaza et al., 2011) and in the Appendix.
Proliferation Assay
The proliferation rates of subconfluent cultures of DPSCs and BMMSCS were assessed by bromodeoxyuridine (BrdU, Invitrogen, Carlsbad, CA, USA) incorporation for 24 hrs with the use of a Zymed BrdU staining kit (Invitrogen), as described previously (Yamaza et al., 2011) 
Population Doublings
The PD assay was repeated with 3 independent isolated cells for each experimental group. The detailed methods are described in the Appendix.
Flow cytometric Analysis
P1 MSCs were stained for cell-surface markers and analyzed by flow cytometry. MSC surface markers CD90, CD29, CD73, and CD106 were selected to verify DPSCs. To exclude the hematological origin, we also examined expression levels of hematological markers CD34, CD45, and CD49, and macrophage marker CD11b. Detailed methods are described in the Appendix.
Immunofluorescence staining
Immunofluorescence staining was performed as described in the Appendix.
Fasl sirnA
For knockdown FasL expression, 0.5 x 10 6 rat or human DPSCs were seeded in a 6-well culture plate. FasL siRNA kits (Ambion, NY and Santa Cruz, CA, USA) were used to treat rat DPSCs and human DPSCs, respectively, according to the manufacturers' protocols.
Western blot Analysis
Western blot was performed as described in the Appendix.
co-culture of DPscs with Activated splenocytes
Co-culture of DPSCs with activated splenocytes was performed as described in the Appendix.
Dextran sulfate sodium (Dss)-induced Mouse colitis and treatment with DPscs
Acute colitis was induced in C57BL/6 mice. The detailed methods were as described previously (Gonzalez-Rey et al., 2009; Zhang et al., 2009) and as in the Appendix. P1 DPSCs were infused into mice with colitis (n = 5 per group) intravenously at day 3 after they were fed with DSS water, with a dose of 1 x 10 5 cells/10 g body weight in 100 μL PBS according to our previous report (Yamaza et al., 2010) . All mice were harvested at day 10 after being fed DSS water and analyzed as previously described (Alex et al., 2009) . The results are representative of 3 independent experiments.
Multi-lineage Differentiation Assay
For in vitro differentiation assay, P1 MSCs were cultured under osteogenic and adipogenic conditions as described in the Appendix. For in vivo osteogenic assay, details are described in the Appendix. statistics SPSS 13.0 was used to perform statistical analysis. Significance was assessed by independent two-tailed Student's t test or analysis of variance (ANOVA). P values less than 0.05 were considered significant.
rEsults

Isolation and characterization of rat DPscs
To isolate rat DPSCs (rDPSCs), we generated single-cell suspensions by enzyme digestion of rat pulp tissue and plated digested cells at a low density. rDPSCs were capable of forming adherent clonogenic colony clusters originating from a single attached cell. These single colonies were similar to primary cultured rat bone marrow MSCs (rBMMSCs), but rDPSCs generated significantly higher numbers of CFU-F than rBMMSCs (Fig. 1A ). The rDPSCs showed elevated cell proliferation rate and self-renewal capability, as determined by BrdU incorporation and population doubling assays, respectively, when compared with rBMMSCs (Figs. 1B, 1C). Flow cytometric analysis showed that the cultured cells are positive for mesenchymal stem cell surface markers (CD90, CD29, CD73, and CD106) and negative for hematological markers (CD34, CD45/CD49) and macrophage marker (CD11b) ( Fig.  1D ). Immunocytochemistry staining confirmed that rDPSCs responded positively to CD90 and CD29 antibodies ( Fig. 1E ). Under osteogenic culture conditions, rDPSCs showed reduced capability to form mineralized nodules, as assessed by Alizarin Red staining and the expression of osteoblastic markers Runx2, ALP, and OCN, as assessed by Western blot analysis, when compared with rBMMSCs ( Fig. 1F ). After 8 wks of subcutaneous transplantation into immunocompromised mice with HA/TCP as a carrier, rDPSCs formed less mineralized tissue when compared with rBMMSCs ( Fig. 1G ). Next, we examined the adipogenic differentiation potential of rDPSCs and found that rDPSCs were able to develop into Oil Red O-positive adipocytes after 4 wks of adipogenic-inductive cultures. Western blot analysis confirmed that rDPSCs showed up-regulation of the adipocyte-specific transcripts PPARγ2 and LPL after adipogenic induction ( Fig. 1H ).
Fasl is required for DPsc-based Immunoregulation
Since FasL plays an important role in BMMSC-induced immune tolerance (Ren et al., 2008; Yamaza et al., 2010 Yamaza et al., , 2011 Zhao et al., 2010) , we hypothesized that FasL would contribute to the immunoregulatory function of DPSCs. To test this hypothesis, we first showed, by flow cytometry, that ~9.36% rDPSCs coexpressed FasL with the mesenchymal marker CD90 ( Fig. 2A) . We further confirmed, by immunocytochemical staining, that rDPSCs co-expressed FasL and CD90 (Fig. 2B ). To examine whether FasL contributes to the immunoregulatory properties of rDPSCs, we used the siRNA approach to knock down FasL expression ( Fig. 2C ). Then we showed that FasL knockdown resulted in a reduced capacity to inhibit T-cell viability in vitro when compared with the control siRNA group (Fig. 2D ). Flow cytometric analysis confirmed that FasL knockdown abrogated rDPSC-induced T-cell apoptosis ( Fig. 2E ). Moreover, we revealed that FasL knockdown reduced rDPSC-mediated inhibition of iTh17 in an in vitro co-culture system when compared with the control siRNA group, whereas FasL knockdown had no significant effect on iTreg ( Fig. 2F ).
To examine the in vivo immunomodulatory properties of rDPSCs, we generated a colitis model in C57BL/6 mice by oral administration of 3% DSS for 7 days . Overall elevation of colitis scores was based on the presence of sustained weight loss and bloody diarrhea/loose feces (Fig. 2G) , with severe colonic transmural inflammation, increased wall thickness, localized inflammatory cell infiltration, and epithelial ulceration ( Fig. 2H ). We found that the systemic infusion of rDPSCs, but not FasL-knockdown rDPSCs by siRNA, protected mice from colitis-related tissue injuries and reduced overall Figure 1 . Characterization of rDPSCs. (A) rDPSCs generated markedly higher numbers of CFU-F than did rBMMSCs. (b) rDPSCs showed an increased proliferation rate in comparison with that of rBMMSCs, as determined by BrdU incorporation assay. (c) rDPSCs showed more elevated population doublings than did rBMMSCs. (D) Flow cytometric analysis showed that rDPSCs expressed surface molecules CD90, CD29, CD73, and CD106. (E) Immunocytochemistry staining further confirmed that rDPSCs expressed CD90 and CD29. (F) Alizarin Red staining showed that rDPSCs had a lower capacity than rBMMSCs to form mineralized nodules after culture in osteoinductive conditions for 4 wks. Western blot analysis confirmed that rDPSCs expressed elevated levels of the osteogenic genes ALP, Runx2, and OCN in the osteoinductive group. (G) rDPSCs were capable of forming mineralized tissue when transplanted subcutaneously into immunocompromised mice with hydroxyapatite tricalcium phosphate (HA/TCP) as a carrier. rDPSCs formed less mineralized tissue when compared with rBMMSCs. B = bone, M = mineralized tissue, BM = bone marrow, H = HA/TCP carrier. (h) Oil Red O staining showed that rDPSCs had reduced capacity to differentiate into adipocytes compared with rBMMSCs at 2 wks post-adipogenic induction. Western blot analysis confirmed that adipogenic induction up-regulated expression of the adipogenic genes PPARγ-2 and LPL.
disease severity compared with the colitis group, along with a marked rescue of body weight (Fig. 2G) and decrease in histological score (Fig. 2H) . Also, the rDPSC treatment group significantly ameliorated colonic transmural inflammation, decreased wall thickness, suppressed epithelial ulceration, and restored normal intestinal architecture. In contrast, the FasLknockdown rDPSC group failed to ameliorate histological phenotypes of colitis (Fig. 2H ). Analysis of these data suggests that FasL is required for rDPSC-mediated immune therapy in the colitis mouse model.
To determine whether FasL plays an important role in the immunomodulation of human DPSCs (hDPSCs), we isolated hDPSCs from human molars and showed that these hDPSCs expressed the MSC-associated markers CD90, CD29, CD73, and CD105 (Fig. 3A) . Also, hDPSCs expressed FasL, as determined by flow cytometry (Fig. 3B ). Knockdown of FasL expression in hDPSCs by siRNA ( Fig. 3C) reduced their capacity to inhibit T-cell proliferation and induce T-cell apoptosis in vitro compared with the control group (Figs. 3D, 3E ).
Fasl Expression has no Impact on DPsc Differentiation
Since FasL expression is important for DPSC-based immunomodulation, it was interesting to determine whether FasL expression was associated with stem cell properties. We used the siRNA approach to knock down FasL expression in DPSCs and found that reduced FasL expression failed to influence DPSC proliferation and differentiation. When FasL expression was knocked down by siRNA, the proliferation rate, as assessed by BrdU incorporation, showed no marked alteration (Figs. 4A). Moreover, expression levels of CD90, CD29, CD73, CD106, CD49, CD34, CD45, and CD11b showed no significant difference between FasL-knockdown and control rDPSCs (Fig. 4B) .
Western blot analysis confirmed that the expression of CD90 was not changed by FasL knockdown (Fig. 4C ). Since DPSCs can differentiate into multiple cell types, such as odontoblasts and adipocytes, we further determined whether FasL knockdown affected their multipotent differentiation capacity. We found that FasL knockdown failed to alter the osteogenic differentiation capacity of rDPSCs, as indicated by Alizarin Red staining, to show mineralized nodule formation, and by Western blot analysis, to show expression of the osteo/odontogenic genes Runx2, ALP, and OCN (Fig. 4D) . We next subcutaneously implanted rDPSCs into immunocompromised mice, using HA/TCP as a carrier. This in vivo implantation assay showed that FasL knockdown did not affect the tissue regeneration capacity of rDPSCs (Fig. 4E) . Additionally, FasL knockdown was unable to alter adipogenic differentiation of rDPSCs, as indicated by the number of Oil Red O-positive cells and expression of the adipogenic genes PPARγ2 and LPL (Fig. 4F ).
DIscussIOn
It has been reported that some connective-tissue-derived cells, such as adipocytes and fibroblasts, shared similar immunomodulatory properties (Halberg et al., 2008; Cappellesso-Fleury et al., 2010) . However, when compared with somatic cells, MSCs are generally considered to be less immunogenic because of low expression levels of major histocompatibility complex (MHC) class I molecules and negativity for MHC class II cells (Le Blanc et al., 2003; Morandi et al., 2008) . MSCs have been proven to possess immunomodulatory properties and have been used clinically to treat autoimmune diseases, such as graft-vs.host disease (GVHD), systemic lupus erythematosus (SLE), and systemic sclerosis (SS) (Le Blanc et al., 2008; Sun et al., 2009) . Given the fact that MSC/ osteoblast lineage constitutes an important niche for hematopoietic stem cells (HSCs), it is reasonable to postulate that MSCs may interact with T-cells in a cellcell-contact manner. The binding of membrane-bound FasL and Fas is an important cell death pathway which mediates apoptosis in several cell types (Mazar et al., 2009; O'Reilly et al., 2009 ). It has been reported that BMMSCs express FasL to induce T-cell apoptosis through the FasL/Fas pathway (Akiyama et al., 2012) . In this study, we found that DPSCs also expressed FasL; thus, we hypothesized that DPSCs might induce T-cell apoptosis and ameliorate diseased phenotypes in mice with colitis.
Although DPSCs share several characteristics with BMMSCs, DPSCs show reduced osteogenic and adipogenic potentials (Gronthos et al., 2000) . Such differences may be partly due to the fact that DPSCs derive from neural crest cells, whereas BMMSCs originate from the mesoderm (Musina et al., 2006; Janebodin et al., 2011) .
The DSS-induced ulcerative colitis mouse model is a wellestablished autoimmune disease model, which is characterized by dysfunction of innate and adaptive immunity, resulting in colonic mucosal injury to the distal small intestine . To evaluate dextran sulfate sodium-induced colitis objectively, we performed histological analysis according to wellestablished methods (Akiyama et al., 2012) . The results are representative of 3 independent experiments. To confirm the role of FasL in DPSC-mediated immunoregulation in vivo, we used this animal model to demonstrate that infusion of rat DPSCs would ameliorate inflammatory-related colonic tissue injury, which is similar to recent studies with human adiposederived and gingival-derived MSCs (Gonzalez-Rey et al., 2009; Zhang et al., 2009 ). The therapeutic mechanism may lie in the reduced colonic infiltration of inflammatory cells and downregulation of inflammatory cytokines, as indicated by analysis of our histological data. Other mechanisms may involve the increased infiltration of regulatory T-cells and the expression of anti-inflammatory cytokine IL-10 at the colonic sites . Interestingly, FasL knockdown in DPSCs resulted in a reduced capacity to ameliorate colitis phenotypes, indicating that FasL is required for DPSC-mediated immunoregulation. Moreover, in vitro co-culture assays demonstrated that DPSCs induced apoptosis of iTh17, but not iTreg, suggesting that such FasL-mediated apoptosis was specific for T-helper cells, but not for Tregs, a finding which was supported by our previous study on bone marrow MSCs (Akiyama et al., 2012) . Additionally, FasL knockdown was unable to alter the multipotent differentiation capacity of DPSCs, suggesting that the role of FasL may be limited to controlling interaction between DPSCs and immune cells.
Our group found that bone marrow MSCs secrete Fasmediated monocyte chemotactic protein 1 (MCP-1) to recruit activated T-cells and then induce T-cell apoptosis. The apoptotic T-cells subsequently trigger macrophages to produce high levels of TGFβ, which, in turn, leads to the up-regulation of CD4 + CD25 + Foxp3 + Tregs to induce ultimate immune tolerance (Akiyama et al., 2012) . Also, several studies have indicated that soluble factors, such as prostaglandin E 2 (PGE 2 ), nitric oxide (NO), indoleamine 2,3-dioxygenase (IDO), and hepatic growth factor (HGF), also contributed to MSC-mediated immunosuppression (Ren et al., 2008; Spaggiari et al., 2008) . Therefore, it is necessary to further elucidate the detailed mechanism by which systemically infused DPSCs regulate the immune system. The fact that FasL does not affect DPSC proliferation and differentiation suggests that expression of FasL in DPSCs contributes only to their ability to interact with immune cells.
In summary, we have demonstrated that DPSCs express FasL and then use FasL to induce T-cell apoptosis. DPSC-mediated immune therapy in colitis mice is associated with FasL-induced T-cell apoptosis.
